ANIX Anixa Biosciences Inc Earnings per share for the last twelve months

Anixa Biosciences, Inc. (ANIX) is implementing automated antibody screening to accelerate cancer therapy. The GURU.Markets system displays the change in the rolling annual EPS, where the value -0.31 represents the most recent figure. The model is based on formula licensing to minimize costs, while business protection relies on patents and strict medical oversight of diagnostic safety.
Summary analytical data breakdowns for Anixa Bio (ANIX)

Net income per share over the last 12 months measures the actual profitability of the business by dividing the final financial result by the total number of securities to evaluate the efficiency of each share. An analysis of the fundamental TTM earnings per share for Anixa Biosciences, Inc. (ANIX) allows for tracking the impact of costs related to third-party CROs and patent R&D, as the virtual model of Anixa Biosciences, Inc. (ANIX) shifts all operational risks to external vendors.